Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2017

01-09-2017 | Editorial

Players of ‘hypoxia orchestra’ – what is the role of FMISO?

Authors: Takuya Toyonaga, Kenji Hirata, Tohru Shiga, Tamaki Nagara

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2017

Login to get access

Excerpt

Hypoxia is one of the most important factors for exacerbating malignancy, including brain tumors [13]. Hypoxia induces radioresistance [4], chemoresistance [5], HRE-related gene transcription [6], and hypermethylation of tumor suppressor genes [7], making tumor cells more aggressive. These phenomena interact with one another such that the entire set of mechanisms could be described as ‘Hypoxia Orchestra playing Symphony Malignancy’. Of the above cascades, the correlation between hypoxia and HRE-related gene transcription has been well studied. The key player is HIF as the ‘principal conductor of the Orchestra’. HIF leads and controls HRE-related gene translation in hypoxia. In normoxia, HIFα is very unstable, easily degraded by HIF hydroxylases. When the oxygen partial pressure is significantly low owing to rapid tumor growth or a large amount of oxygen consumption, HIF hydroxylases are inactivated, making HIFα more stable. Stable HIFα makes a conjugate with HIF1β, and that conjugates bind to HRE on the DNA and drives transcription of proteins from downstream genes that impact tumor malignancy, such as cell migration, energy metabolism, angiogenic signaling, transcriptional regulation, growth and apoptosis [6]. Over many years, L Bekaert, J.S. Guillamo and coauthors have contributed a significant body of research concerning glioma. Maintaining their focus on malignancy and the prognosis of glioma, they approached these subjects from the standpoints of treatment strategy [8, 9], gene mutation [10], the methylation of DNA [11], and molecular mechanisms [12]. They also performed imaging studies of glioma [13, 14]. …
Literature
1.
go back to reference Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14(9):2623–30. doi:10.1158/1078-0432.CCR-07-4995.CrossRefPubMedPubMedCentral Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14(9):2623–30. doi:10.​1158/​1078-0432.​CCR-07-4995.CrossRefPubMedPubMedCentral
2.
go back to reference Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41(10):1870–8. doi:10.1007/s00259-014-2776-9.CrossRefPubMed Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41(10):1870–8. doi:10.​1007/​s00259-014-2776-9.CrossRefPubMed
3.
4.
go back to reference Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9(4):442–58.CrossRefPubMedPubMedCentral Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9(4):442–58.CrossRefPubMedPubMedCentral
9.
go back to reference Duntze J, Litre CF, Eap C, Theret E, Debreuve A, Jovenin N, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol. 2013;20(6):2065–72. doi:10.1245/s10434-012-2764-x.CrossRefPubMed Duntze J, Litre CF, Eap C, Theret E, Debreuve A, Jovenin N, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol. 2013;20(6):2065–72. doi:10.​1245/​s10434-012-2764-x.CrossRefPubMed
11.
go back to reference Lechapt-Zalcman E, Levallet G, Dugue AE, Vital A, Diebold MD, Menei P, et al. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encodedprotein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer. 2012;118(18):4545–54. doi:10.1002/cncr.27441. Lechapt-Zalcman E, Levallet G, Dugue AE, Vital A, Diebold MD, Menei P, et al. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encodedprotein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer. 2012;118(18):4545–54. doi:10.​1002/​cncr.​27441.
12.
go back to reference Guillamo JS, de Bouard S, Valable S, Marteau L, Leuraud P, Marie Y, et al. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res. 2009;15(11):3697–704. doi:10.1158/1078-0432.CCR-08-2042.CrossRefPubMed Guillamo JS, de Bouard S, Valable S, Marteau L, Leuraud P, Marie Y, et al. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res. 2009;15(11):3697–704. doi:10.​1158/​1078-0432.​CCR-08-2042.CrossRefPubMed
13.
go back to reference Corroyer-Dulmont A, Peres EA, Petit E, Guillamo JS, Varoqueaux N, Roussel S, et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on muMRI and muPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro-Oncology. 2013;15(1):41–56. doi:10.1093/neuonc/nos260.CrossRefPubMed Corroyer-Dulmont A, Peres EA, Petit E, Guillamo JS, Varoqueaux N, Roussel S, et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on muMRI and muPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro-Oncology. 2013;15(1):41–56. doi:10.​1093/​neuonc/​nos260.CrossRefPubMed
15.
go back to reference Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60(24):7075–83.PubMed Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60(24):7075–83.PubMed
16.
go back to reference De Bouard S, Guillamo JS, Christov C, Lefevre N, Brugieres P, Gola E, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum Gene Ther. 2003;14(9):883–95. doi:10.1089/104303403765701178.CrossRefPubMed De Bouard S, Guillamo JS, Christov C, Lefevre N, Brugieres P, Gola E, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum Gene Ther. 2003;14(9):883–95. doi:10.​1089/​1043034037657011​78.CrossRefPubMed
19.
go back to reference Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39(5):760–70. doi:10.1007/s00259-011-2037-0.CrossRefPubMed Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39(5):760–70. doi:10.​1007/​s00259-011-2037-0.CrossRefPubMed
20.
go back to reference Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. doi:10.1007/s00401-016-1545-1.CrossRefPubMed Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. doi:10.​1007/​s00401-016-1545-1.CrossRefPubMed
21.
go back to reference Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, et al. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging. 2016;43(8):1469–76. doi:10.1007/s00259-016-3320-x.CrossRefPubMed Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, et al. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging. 2016;43(8):1469–76. doi:10.​1007/​s00259-016-3320-x.CrossRefPubMed
Metadata
Title
Players of ‘hypoxia orchestra’ – what is the role of FMISO?
Authors
Takuya Toyonaga
Kenji Hirata
Tohru Shiga
Tamaki Nagara
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3754-9

Other articles of this Issue 10/2017

European Journal of Nuclear Medicine and Molecular Imaging 10/2017 Go to the issue